Enpatoran Improves BICLA Response in SLE but Misses Primary Endpoint

A phase 2 trial published in The Lancet on May 9, 2026, has provided results regarding the use of enpatoran, a Toll-like receptor 7/8 inhibitor, for the treatment of patients with moderate-to-severe systemic lupus erythematosus (SLE).

The findings indicate that enpatoran improved BICLA response rates when compared to a placebo. The BICLA response is a measure used to evaluate changes in disease activity for patients with lupus.

Despite the improvement in response rates, the study did not meet its primary objective. The trial failed to demonstrate a statistically significant dose-dependent effect on disease activity based on the BICLA response.

The data were derived from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial. This specific study design was intended to evaluate how different doses of the inhibitor affected the progression and activity of the disease.

Regarding the safety of the medication, the study found that enpatoran was well tolerated across all dose groups involved in the trial.

The results suggest a divergence between the drug’s general ability to improve response rates and the ability to establish a clear, statistically significant relationship between the dose administered and the resulting level of disease activity improvement.